Trial Profile
A phase I study of first-line monotherapy with nivolumab to evaluate the efficacy and safety in patients (pts) with chemotherapy-naïve advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 19 Jan 2016 New trial record